Get started
Author

D. Zitnjak

Observed names: Daniela Zitnjak, Daniela Žitnjak, Žitnjak, Daniela
ORCID: 0009-0006-0310-1044
Observed ORCID: 0009-0006-0310-1044
OpenAlex ID: A5045915161
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
2020 · Per Pfeiffer, Mette Yilmaz, et al. · The Lancet Oncology · 240
Neoadjuvant Chemotherapy vs Upfront Surgery in Patients With Locally Advanced Colon Cancer: A Randomized Clinical Trial
2026 · Lars Henrik Jensen, Monica Kjaer, et al. · JAMA Surgery · 11
Randomized study evaluating trifluridine/tipiracil (TAS-102) versus + trifluridine/tipiracil + bevacizumab as last-line therapy in patients with chemorefractory unresectable metastatic colorectal cancer (mCRC).
2019 · Per Pfeiffer, Mette Yilmaz, et al. · Journal of Clinical Oncology · 6
Demographic and Clinicopathologic Features of Patients With Primary Breast Cancer Treated Between 1997 and 2010: a Single Institution Experience.
2015 · Daniela Žitnjak, Željko Soldić, et al. · PubMed · 5
PDF
Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial
2019 · P. Pfeiffer, M. Yilmaz, et al. · Annals of Oncology · 4
Long-Time Survival of a Patient with Metastatic Pancreatic Cancer: A Case Report
2011 · Željko Soldić, Daniela Žitnjak, et al. · Case Reports in Oncology · 3
Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC
2026 · Rikke Andersen, Mette Syberg Jespersen, et al. · European Journal of Cancer · 2
PDF
1547P Clinical outcomes of patients with acquired resistance to checkpoint inhibitors in melanoma, renal cell carcinoma and non-small cell lung cancer
2025 · M.J. Syberg, R. Andersen, et al. · Annals of Oncology · 1
PDF
PD-7 Updated survival analysis of the Danish randomized study comparing trifluridine/tipiracil with or without bevacizumab in patients with chemo-refractory metastatic colorectal cancer
2020 · P. Pfeiffer, S. Winther, et al. · Annals of Oncology · 1
PDF
Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC)
2019 · C. Qvortrup, M. Yilmaz, et al. · Annals of Oncology
PDF
Koštani fenotip miševa s transgenom za interleukin 7 (IL-7) [Bone phenotype of IL-7 transgenic mice]
2009 · Žitnjak, Daniela · Repository of the Medical Faculty of the University of Zagreb (University of Zagreb)
Works count: 11
Citation count: 273
H-index: 4
I10-index: 2
Year
Topic
Type